Smithkline Corporation v. Sterling Drug, Inc.

406 F. Supp. 52, 189 U.S.P.Q. (BNA) 268, 1975 U.S. Dist. LEXIS 11519
CourtDistrict Court, D. Delaware
DecidedJuly 9, 1975
DocketCiv. A. 74-266
StatusPublished
Cited by15 cases

This text of 406 F. Supp. 52 (Smithkline Corporation v. Sterling Drug, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Smithkline Corporation v. Sterling Drug, Inc., 406 F. Supp. 52, 189 U.S.P.Q. (BNA) 268, 1975 U.S. Dist. LEXIS 11519 (D. Del. 1975).

Opinion

OPINION

MURRAY M. SCHWARTZ, District Judge.

FACTS

This dispute arises from defendant Sterling Drug, Inc.’s (“Sterling”) motion to transfer this litigation, pursuant to 28 U.S.C. § 1404(a), 1 to the Eastern District of Pennsylvania. Before reaching the legal issues raised by plaintiff SmithKline Corporation’s (“SmithKline”) opposition to Sterling’s motion, it is necessary to briefly describe the facts which spawned this and other related suits.

On December 1, 1960 Sterling filed a patent application (Serial No. 72,844) disclosing and claiming a broad group of generic benzomorphan compounds that included a compound known generically as pentazocine. 2 Because, on March 10, 1960, SmithKline had filed an application (Serial No. 13,982) which also disclosed and claimed certain benzomorphan compounds, the U. S. Patent Office on July 7, 1961 declared an Interference 3 (No. 91,896) involving the patent applications of the present parties. 4 Although TAL-WIN was not involved in the interference proceeding, the parties, on September 15, 1964, entered into an agreement whereby SmithKline transferred its rights to TALWIN in exchange for royalties based upon defendant’s sales of the drug. Payment of royalties was to commence upon the Patent Office’s determination of priority of invention and subsequent issuance of a patent. 5 On October 3. 1967 the Patent Office issued a patent (No. 3,345,373) covering TALWIN to SmithKline. 6 Thereafter, upon petition of Sterling, a second Interference was declared to determine priority of invention with respect to TALWIN.

During the pendency of the interference two separate suits were filed by Sterling in the U. S. District Court for the Eastern District of Pennsylvania. The first, Civil Action No. 70-1943, sought injunctive, declaratory and com *54 pensatory relief with respect to the continued existence of the royalty agreement and the enforceability of Smith-Kline’s patent. That suit, filed on July 15, 1970, was dismissed without prejudice pursuant to a Termination Agreement between the parties dated November 18, 1970, which inter alia, superceded the prior agreement of September 15, 1964. The second suit, Mise. Civil Action No. 70-302, filed on December 21, 1970, was an ancillary proceeding brought under 35 U.S.C. § 24 for the purpose of obtaining discovery in the interference proceeding.

On June 20, 1974 the Board of Patent Interference decided the priority of invention question adversely to SmithKline and adhered to this decision by refusing to reconsider it on September 27, 1974. Thereafter, SmithKline took an appeal under 35 U.S.C. § 141 7 contesting the Board’s decision. On November 14, 1974, Sterling, pursuant to 35 U.S.C. § 141 elected to proceed in a district court civil action under 35 U.S.C. § 146. 8 On the same day, Sterling brought suit in the United States District Court for the Eastern District of Pennsylvania seeking a declaration of the invalidity and unenforceability of SmithKline’s earlier-issued patent, the return of payments previously made under the royalty agreement and the recission and reformation of the earlier agreements. That suit, Civil Action No. 74-2957, was assigned to the same judge who adjudicated Mise. Civil Action No. 70 — 302. 9 Thereafter, on December 10, 1974, SmithKline filed the instant action in this Court pursuant to 35 U.S.C. § 146 to appeal the Board’s adverse finding on the priority of invention issue.

Plaintiff SmithKline’s principal grounds of opposition to Sterling’s motion to transfer this suit to the Eastern District of Pennsylvania are as follows: (1) transfer is unwarranted in that it would not serve the “interests of justice”; (2) such transfer is barred by 35 U.S.C. §§ 141 and 146 because a transfer of this litigation would abrogate plaintiff’s exclusive right to designate a forum of its choice under 35 U.S.C. § 146.

LEGAL ISSUES

A. Is Transfer Warranted?

At the outset, it is clear that the moving party on a motion to transfer under section 1404(a) bears the burden of proving that any such transfer will be in the best interest of justice. Kaiser Industries Corporation v. Wheeling-Pittsburgh Steel Corporation, 328 F.Supp. 365, 368 (D.Del.1971). This is because a plaintiff’s choice of forum is entitled to substantial weight and is thus “a paramount consideration in any determination of a transfer request . . .” Shutte v. Armco Steel Corporation, 431 F.2d 22, 25 (3d Cir. 1970), cert. denied, 401 U.S. 910, 91 S.Ct. 871, 27 L.Ed.2d 808 (1971). But see A. Olinick & Sons v. Dempster Bros., Inc., 365 F.2d 439, 444-45 (2d Cir. 1966); Sweetheart Plastics, Inc. v. Illinois Tool Works, Inc., 267 F.Supp. 938, 942, n. 9 (S.D.N.Y.1967). Cf. Norwood v. Kirkpatrick, 349 U.S. 29, 32, 75 S.Ct. 544, 99 L.Ed. 789 (1955). Since a plaintiff’s forum choice is accorded such deference this Court has stated that “ . . . transfer should be denied where the factors to be considered are evenly balanced or only slightly fa *55 vor a transfer . . . .” Scovill Manufacturing Co. v. Sunbeam Corporation, 357 F.Supp. 943, 946 (D.Del.1973) citing Aetna Casualty & Surety Co. v. Singer-General Precision, Inc., 323 F.Supp. 1141, 1143 (D.Del.1971).

The initial requirement for transfer to another forum is that the putative transferee court be a district “where it might have been brought.” 28 U.S.C. § 1404(a). Van Dusen v. Barrack, 376 U.S. 612, 84 S.Ct. 805, 11 L.Ed.2d 945 (1964). See generally 1 Moore’s Federal Practice

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Erbamont Inc. v. Cetus Corp.
720 F. Supp. 387 (D. Delaware, 1989)
Chrysler Capital Corp. v. Woehling
663 F. Supp. 478 (D. Delaware, 1987)
Fairfax Dental (Ireland) Ltd. v. S.J. Filhol Ltd.
645 F. Supp. 89 (E.D. New York, 1986)
Lake Ex Rel. Lake v. Richardson-Merrell, Inc.
538 F. Supp. 262 (N.D. Ohio, 1982)
Pall Corp. v. Bentley Laboratories, Inc.
523 F. Supp. 450 (D. Delaware, 1981)
Houchins v. Florida East Coast Ry. Co.
388 So. 2d 1287 (District Court of Appeal of Florida, 1980)
Allison v. Superior Court
99 Cal. App. 3d 993 (California Court of Appeal, 1979)
Blumenthal v. Management Assistance, Inc.
480 F. Supp. 470 (N.D. Illinois, 1979)
Lee v. Ohio Casualty Insurance
445 F. Supp. 189 (D. Delaware, 1978)
McGuire v. Singer Co.
441 F. Supp. 210 (Virgin Islands, 1977)
Industrial Union Department v. Bingham
570 F.2d 965 (D.C. Circuit, 1977)
Phillips Petroleum Co. v. Federal Energy Administration
435 F. Supp. 1234 (D. Delaware, 1977)

Cite This Page — Counsel Stack

Bluebook (online)
406 F. Supp. 52, 189 U.S.P.Q. (BNA) 268, 1975 U.S. Dist. LEXIS 11519, Counsel Stack Legal Research, https://law.counselstack.com/opinion/smithkline-corporation-v-sterling-drug-inc-ded-1975.